Skip to main content
Log in

A case of malignant pheochromocytoma with early intense uptake and immediate rapid washout of99mTc-tetrofosmin characterizing the overexpression of anti-apoptotic Bcl-2

  • Case Report
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Defective apoptotic program due to the overexpression of the anti-apoptotic Bcl-2 protein of the outer mitochondrial membrane may be a cause of the poor response of malignant pheochromocytoma to131I-MIBG therapy. We report a case of malignant pheochromocytoma which showed early intense uptake and immediate rapid washout of99mTc-tetrofosmin characterizing the overexpression of anti-apoptotic Bcl-2 and which was refractory to131I-MIBG therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Del Vecchio S, Zanntti A, Aloj L, Caraco C, Ciamiello A, Salvatore M. Inhibition of early99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma.Eur J Nucl Med Mol Imaging 2003; 30: 879–887.

    PubMed  Google Scholar 

  2. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line.Blood 1993; 81: 151–157.

    PubMed  CAS  Google Scholar 

  3. Reed JC. Apoptosis-regulating proteins as a target for drug discovery.Trends Mol Med 2001; 7: 314–319.

    Article  PubMed  CAS  Google Scholar 

  4. Moretti JL, Hauet N, Caglar M, Rebillard O, Burak Z. To use MIBI or not to use MIBI? That is the question when assessing tumor cells.Eur J Nucl Med Mol Imaging 2005; 32: 836–842.

    Article  PubMed  Google Scholar 

  5. Vergote J, Di Benedetto M, Morretti JL, Azaloux H, Kouyoumdjian JC, Kraemer M, et al. Could99mTc-MIBI be used to visualize the apoptotic MCF7 human breast cancer cells?Cell Mol Biol (Noisy-le-grand) 2001; 47: 467–471.

    CAS  Google Scholar 

  6. Kostakoglu L, Elahi N, Kiratli P, Ruacan S, Sayek I, Baltali E, et al. Clinical validation of the influence of P-glycopro-tein on technetium-99m-sestamibi uptake in malignant tumors.J Nucl Med 1997; 38: 1003–1008.

    PubMed  CAS  Google Scholar 

  7. Del Vecchio S, Ciarmiello A, Potena MI, Carriero MV, Mainolfi C, Botti G, et al.In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m-sestamibi scan in untreated breast cancer patients.Eur J Nucl Med 1997; 24: 150–159.

    Article  PubMed  CAS  Google Scholar 

  8. Loh KC, Fitzgerald PA, Mattthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with io-dine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.J Endocrinol Invest 1997; 20: 648–658.

    PubMed  CAS  Google Scholar 

  9. Krijger RR, van der Harst E, van der Ham F, Stijnen T, Dinjens WK, Koper JW, et al. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in pheochromocytoma.J Pathol 1999; 188: 51–55.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shigetoshi Wakasugi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wakasugi, S., Kinouchi, T., Taniguchi, H. et al. A case of malignant pheochromocytoma with early intense uptake and immediate rapid washout of99mTc-tetrofosmin characterizing the overexpression of anti-apoptotic Bcl-2. Ann Nucl Med 20, 325–328 (2006). https://doi.org/10.1007/BF02984651

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02984651

Key words

Navigation